Cumberland Pharma Soars on $100M Apotex Deal

Cumberland Pharmaceuticals shares jumped about 80% after announcing a $100 million cash deal with Apotex to sell its branded drug line.
The transaction, pending shareholder approval, lets Cumberland retain its pipeline and majority stake in Cumberland Emerging Technologies to focus on orphan drugs.
CEO A.J. Kazimi said the deal unlocks shareholder value and enables focus on large market opportunities from its pipeline candidates.
Cumberland reported breakthrough Phase II results for ifetroban in Duchenne‑related cardiomyopathy, with FDA orphan, rare pediatric disease and Fast Track designations.